Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: A clinicopathologic and molecular comparison

International Journal of Gynecological Pathology

Volumn 16, Issue 4, 1997, Pages 354-360

  Jones, Mirka W ^a   Kounelis, Sophia ^a   Hsu, Chia ^a   Papadaki, Helen ^a   Bakker, Anke ^b   Swalsky, Patricia A ^b   Finkelstein, Sydney D ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Endometrial carcinoma; K ras 2 mutation; P53 mutation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; UTERUS CARCINOMA;

EID: 0030768640     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199710000-00010     Document Type: Article

References (23)

1. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ (ed), Blaustein's Pathology of the Female Genital Tract, IV Edition. New York: Springer-Verlag, 1994:439-86.
2. Parazzini F, Vecchia CL, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
3. Silverberg SG, Sassano N, Yajima A. Endometrial carcinoma in Miyagi prefecture, Japan: histopathologic analysis of a cancer registry-based series and comparison with cases in American women. Cancer 1982;49:1504-10.
4. Zaino RJ, Kurman Rj, Diana KL, Morrow CP. The utility of revised International Federation of Gynecology and Obstetrics histologic grading of endometrial carcinoma using a defined nuclear grading system. Cancer 1995;75:81-6.
5. Sasano H, Comerford J, Wilkinson DS, Schwartz A, Garrett CT. Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry. Cancer 1990;65: 1545-51.
6. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. P-53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992; 98:81-7.
7. Enomoto T, Fujita M, Inoue M, et al. Alterations of the p-53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human endometrium. Cancer Res 1993;53:1883-88.
8. Okamoto A, Sameshima Y, Yamada Y, et al. Allelic loss on chromosome 17p and p-53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991;51:5632-6.
9. Risinger J, Georgette AD, Ignar-Townbridge D, et al. P-53 mutations in human endometrial carcinoma. Mol Carcinog 1992;5: 250-3.
10. Kohler M, Berchuck A, Davidoff A, et al. Overexpression of p-53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
11. Ambros RA, Vigna PA, Figge J, et al. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p-53. Cancer 1994;73:1686.
12. Jiko K, Sasano H, Ito K, Ozawa N, Sato S, Yajima A. Immunohistochemical and in situ hybridization analysis of p-53 in human endometrial carcinoma of the uterus. Anticancer Res 1993;13:305.
13. Ambros RA, Ross JS, Bhaskar VS, et al. P-53 gene status in endometrial carcinomas showing diffuse positivity for p-53 protein by immunohistochemical analysis. Mod Pathol 1995;8:441-5.
14. Enomoto T, Inuoe M, Perantoni AO, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991;51:5308-14.
15. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garret CT. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992;52:2777-81.
16. Caduff RF, Johnson CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146: 182-8.
17. Lester DR, Gauchi MN. Point mutations at codon 12 of C-K-ras in human endometrial carcinomas. Cancer Lett 1990;51:7-10.
18. Ignar Trowbridge D, Risinger JI, et al. Mutations of the Ki-ras oncogene in endometrial carcinoma. Am J Obstet Gynecol 1992; 167:227-32.
19. Fujimoto I, Shimizu Y, Hirai Y, et al. Studies on ras oncogene activation in endometrial carcinoma. Gvnecol Oncol 1993;48:196-202.
20. Sasaki H, Nishii H, Takahashi H, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:1906-10.
21. Imamura T, Arima T, Kato H, Miyamoto S, Sasazuki T, Wake N. Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas. Int J Cancer 1992;51:47-52.
22. Wu T-T, Barnes L, Bakker A, Swalsky PA, Finkelstein SD. K-ras-2 and p-53 genotyping of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Mod Pathol 1996;9:199-204.
23. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.